190 related articles for article (PubMed ID: 25715778)
1. Evaluation of the drug sensitivity and expression of 16 drug resistance-related genes in canine histiocytic sarcoma cell lines.
Asada H; Tomiyasu H; Goto-Koshino Y; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2015 Jun; 77(6):677-84. PubMed ID: 25715778
[TBL] [Abstract][Full Text] [Related]
2. PTPN11 mutations in canine and human disseminated histiocytic sarcoma.
Hédan B; Rault M; Abadie J; Ulvé R; Botherel N; Devauchelle P; Copie-Bergman C; Cadieu E; Parrens M; Alten J; Zalcman EL; Cario G; Damaj G; Mokhtari K; Le Loarer F; Coulomb-Lhermine A; Derrien T; Hitte C; Bachelot L; Breen M; Gilot D; Blay JY; Donadieu J; André C
Int J Cancer; 2020 Sep; 147(6):1657-1665. PubMed ID: 32212266
[TBL] [Abstract][Full Text] [Related]
3. A novel canine histiocytic sarcoma cell line: initial characterization and utilization for drug screening studies.
Takada M; Parys M; Gregory-Bryson E; Vilar Saavedra P; Kiupel M; Yuzbasiyan-Gurkan V
BMC Cancer; 2018 Mar; 18(1):237. PubMed ID: 29490634
[TBL] [Abstract][Full Text] [Related]
4. Influence of a survivin suppressor YM155 on the chemoresistance of canine histiocytic sarcoma cells.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Vet J; 2015 Sep; 205(3):375-80. PubMed ID: 26048444
[TBL] [Abstract][Full Text] [Related]
5. A 2-base insertion in exon 5 is a common mutation of the TP53 gene in dogs with histiocytic sarcoma.
Asada H; Tsuboi M; Chambers JK; Uchida K; Tomiyasu H; Goto-Koshino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2017 Oct; 79(10):1721-1726. PubMed ID: 28867679
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis inhibitor of macrophage (AIM) reduces cell number in canine histiocytic sarcoma cell lines.
Uchida M; Saeki K; Maeda S; Tamahara S; Yonezawa T; Matsuki N
J Vet Med Sci; 2016 Oct; 78(9):1515-1520. PubMed ID: 27246397
[TBL] [Abstract][Full Text] [Related]
7. Effect of dasatinib in a xenograft mouse model of canine histiocytic sarcoma and in vitro expression status of its potential target EPHA2.
Ito K; Miyamoto R; Tani H; Kurita S; Kobayashi M; Tamura K; Bonkobara M
J Vet Pharmacol Ther; 2018 Feb; 41(1):e45-e48. PubMed ID: 28833247
[TBL] [Abstract][Full Text] [Related]
8. Identification of dasatinib as an in vitro potent growth inhibitor of canine histiocytic sarcoma cells.
Ito K; Kuroki S; Kobayashi M; Ono K; Washizu T; Bonkobara M
Vet J; 2013 Jun; 196(3):536-40. PubMed ID: 23369384
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the two-base insertion mutation in the TP53 gene in canine histiocytic sarcoma.
Asada H; Tomiyasu H; Okada K; Chambers JK; Goto-Koshino Y; Uchida K; Kagawa Y; Ohno K; Tsujimoto H
Res Vet Sci; 2019 Jun; 124():57-60. PubMed ID: 30852355
[TBL] [Abstract][Full Text] [Related]
10. Variations in Histiocytic Differentiation of Cell Lines From Canine Cerebral and Articular Histiocytic Sarcomas.
Thongtharb A; Uchida K; Chambers JK; Nakayama H
Vet Pathol; 2017 May; 54(3):395-404. PubMed ID: 28178429
[TBL] [Abstract][Full Text] [Related]
11. Array-based comparative genomic hybridization-guided identification of reference genes for normalization of real-time quantitative polymerase chain reaction assay data for lymphomas, histiocytic sarcomas, and osteosarcomas of dogs.
Tsai PC; Breen M
Am J Vet Res; 2012 Sep; 73(9):1335-43. PubMed ID: 22924713
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a combination chemotherapy protocol including lomustine and doxorubicin in canine histiocytic sarcoma.
Cannon C; Borgatti A; Henson M; Husbands B
J Small Anim Pract; 2015 Jul; 56(7):425-9. PubMed ID: 25828786
[TBL] [Abstract][Full Text] [Related]
13. Survivin suppressor (YM155) enhances chemotherapeutic efficacy against canine histiocytic sarcoma in murine transplantation models.
Yamazaki H; Takagi S; Hosoya K; Okumura M
Res Vet Sci; 2015 Apr; 99():137-44. PubMed ID: 25744435
[TBL] [Abstract][Full Text] [Related]
14. Epirubicin in the treatment of canine histiocytic sarcoma: sequential, alternating and rescue chemotherapy.
Mason SL; Finotello R; Blackwood L
Vet Comp Oncol; 2018 Mar; 16(1):E30-E37. PubMed ID: 28621004
[TBL] [Abstract][Full Text] [Related]
15. Nimustine Treatment of 11 Cases of Canine Histiocytic Sarcoma.
Tani H; Kurita S; Miyamoto R; Sawada H; Fujiwara-Igarashi A; Michishita M; Azakami D; Hasegawa D; Tamura K; Bonkobara M
J Am Anim Hosp Assoc; 2020; 56(3):146. PubMed ID: 32182105
[No Abstract] [Full Text] [Related]
16. Molecular characterization of canine SHP2 mutants and anti-tumour effect of SHP2 inhibitor, SHP099, in a xenograft mouse model of canine histiocytic sarcoma.
Tani H; Miyamoto R; Nagashima T; Michishita M; Tamura K; Bonkobara M
Vet Comp Oncol; 2022 Mar; 20(1):109-117. PubMed ID: 34241941
[TBL] [Abstract][Full Text] [Related]
17. mRNA sequencing analysis and growth inhibitory effects of palbociclib on cell lines from canine histiocytic proliferative disorders.
Hirabayashi M; Chambers JK; Tani A; Tomiyasu H; Motegi T; Rimpo K; Nakayama H; Uchida K
Vet Comp Oncol; 2022 Sep; 20(3):587-601. PubMed ID: 35278028
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of dacarbazine as a rescue agent for histiocytic sarcoma in dogs.
Kezer KA; Barber LG; Jennings SH
Vet Comp Oncol; 2018 Mar; 16(1):77-80. PubMed ID: 28419676
[TBL] [Abstract][Full Text] [Related]
19. Phase II, open-label trial of single-agent CCNU in dogs with previously untreated histiocytic sarcoma.
Rassnick KM; Moore AS; Russell DS; Northrup NC; Kristal O; Bailey DB; Flory AB; Kiselow MA; Intile JL
J Vet Intern Med; 2010; 24(6):1528-31. PubMed ID: 21155191
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates significantly increase the activity of doxorubicin or vincristine against canine malignant histiocytosis cells.
Hafeman SD; Varland D; Dow SW
Vet Comp Oncol; 2012 Mar; 10(1):44-56. PubMed ID: 22236140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
